7 New Launches in the UK Market During Q1
Farmak International’s UK team launched seven new products in the first quarter of 2026, strengthening the company’s market presence.
These additions span several therapeutic areas, with a primary focus on hospital and specialist care medicines.
These include products for:
▶ Intensive care and anaesthesiology.
▶ Diagnostic imaging.
▶ Cardiology.
▶ Ophthalmology.
▶ Musculoskeletal conditions.
The UK market experienced the most significant portfolio growth this quarter, supporting Farmak International’s efforts to enhance its presence and partnerships with local stakeholders.
What I value most this quarter is how our UK/IE team has combined portfolio growth with strong partner collaboration. That’s exactly how we plan to continue developing our presence in the UK
Marc Hourigan Farmak International UK
Additionally, the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted 12 new marketing authorizations in Q1 2026, covering medicines in several therapeutic areas:
▶ Cardiovascular diseases (e.g., antihypertensives, antiplatelet agents).
▶ Infectious diseases (antibiotics).
▶ Vitamin D deficiency and related metabolic conditions.
▶ Ear, nose, and throat (ENT) conditions (anti-inflammatory treatments).
These developments demonstrate the company’s ongoing UK portfolio expansion and commitment to making established therapies available across multiple treatment areas.
About Farmak International
Farmak International is the global commercial platform of Farmak Group, delivering high-quality complex generics and hospital medicines to partners worldwide. With operations across Europe and other regions, the company supports full-cycle collaboration, from development and regulatory expertise to supply and lifecycle management, guided by its mission to provide quality medicines globally.
Product availability, regulatory status, and commercialization rights vary by country and may be restricted by intellectual property rights or other legal requirements. Products are not offered for sale or supplied where such rights prohibit sale or would result in intellectual property rights infringement. Customers are responsible for verifying all relevant intellectual property rights (including patents and SPCs) and for ensuring compliance with local laws.
